TG Therapeutics, Inc.
TGTXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeTG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United. Valued at $8.39B, TGTX is a mid-cap name in its sector. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Market Cap
$8.39B
Beta
1.80
P/E (TTM)
19.71
P/E (Fwd)
20.23
EPS (TTM)
$2.78
EPS (Fwd)
$2.71
ROE
100.3%
ROA
7.3%
Cash
$552.2M
Total Debt
$754.4M
Free CF
$59.1M
52W Change
62.6%
Annual Financials
Cash vs Debt
Where TGTX stands vs its 150-day and 200-day moving averages
As of the October 2, 2026 close, TGTX finished 19.26% above its 150-day moving average ($44.96) and 30.15% above its 200-day moving average ($41.20). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TGTX overbought or oversold?
At the October 2, 2026 close, TGTX's RSI(14) was 49.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
TG Therapeutics, Inc. carries $754.4M in total debt against $552.2M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $59.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 100.3% points to exceptionally high capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 7.3% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $2.8M (2022) to $616.3M (2025), reflecting a 22029% increase over the period.
A beta of 1.80 means TGTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for TG Therapeutics, Inc. and its sector.